World Investment Advisors Sells 18,094 Shares of CVS Health Corporation $CVS

World Investment Advisors trimmed its position in shares of CVS Health Corporation (NYSE:CVS) by 24.6% in the first quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 55,315 shares of the pharmacy operator’s stock after selling 18,094 shares during the period. World Investment Advisors’ holdings in CVS Health were worth $3,973,000 as of its most recent SEC filing.

Other hedge funds and other institutional investors also recently made changes to their positions in the company. Norges Bank acquired a new position in shares of CVS Health during the 4th quarter worth about $1,666,265,000. Wellington Management Group LLP grew its holdings in CVS Health by 193.2% in the 4th quarter. Wellington Management Group LLP now owns 18,564,392 shares of the pharmacy operator’s stock valued at $1,473,270,000 after buying an additional 12,233,675 shares during the last quarter. Amundi increased its position in CVS Health by 95.3% in the 3rd quarter. Amundi now owns 7,453,980 shares of the pharmacy operator’s stock worth $572,665,000 after buying an additional 3,637,943 shares during the period. Capital Research Global Investors increased its position in CVS Health by 24.5% in the 3rd quarter. Capital Research Global Investors now owns 11,469,250 shares of the pharmacy operator’s stock worth $864,667,000 after buying an additional 2,253,531 shares during the period. Finally, Arrowstreet Capital Limited Partnership lifted its holdings in shares of CVS Health by 70.5% during the third quarter. Arrowstreet Capital Limited Partnership now owns 5,294,134 shares of the pharmacy operator’s stock worth $399,125,000 after buying an additional 2,188,307 shares during the last quarter. 80.66% of the stock is owned by institutional investors and hedge funds.

CVS Health Stock Up 0.0%

Shares of CVS stock opened at $104.74 on Monday. The stock has a market cap of $133.64 billion, a P/E ratio of 46.14, a price-to-earnings-growth ratio of 1.03 and a beta of 0.61. CVS Health Corporation has a one year low of $58.50 and a one year high of $106.15. The stock has a fifty day moving average price of $94.56 and a 200 day moving average price of $83.31. The company has a debt-to-equity ratio of 0.78, a current ratio of 0.87 and a quick ratio of 0.66.

CVS Health (NYSE:CVS) last announced its quarterly earnings results on Wednesday, May 6th. The pharmacy operator reported $2.57 earnings per share (EPS) for the quarter, beating the consensus estimate of $2.21 by $0.36. CVS Health had a net margin of 0.72% and a return on equity of 11.88%. The firm had revenue of $100.43 billion for the quarter, compared to analyst estimates of $94.99 billion. During the same quarter in the previous year, the firm posted $2.25 EPS. The business’s revenue for the quarter was up 6.2% on a year-over-year basis. CVS Health has set its FY 2026 guidance at 7.300-7.500 EPS. Analysts predict that CVS Health Corporation will post 7.44 earnings per share for the current year.

Insider Transactions at CVS Health

In related news, Director Larry Robbins sold 370,462 shares of the company’s stock in a transaction dated Thursday, May 21st. The shares were sold at an average price of $93.45, for a total value of $34,619,673.90. Following the sale, the director owned 4,824,799 shares of the company’s stock, valued at $450,877,466.55. The trade was a 7.13% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available through this hyperlink. Also, EVP Tilak Mandadi sold 69,551 shares of the firm’s stock in a transaction dated Friday, May 8th. The stock was sold at an average price of $89.58, for a total transaction of $6,230,378.58. Following the transaction, the executive vice president owned 10,133 shares of the company’s stock, valued at approximately $907,714.14. This represents a 87.28% decrease in their position. The disclosure for this sale is available in the SEC filing. In the last three months, insiders sold 3,441,551 shares of company stock worth $323,703,977. 0.85% of the stock is currently owned by insiders.

Wall Street Analyst Weigh In

Several equities research analysts have recently issued reports on CVS shares. Truist Financial raised their price objective on shares of CVS Health from $102.00 to $108.00 and gave the stock a “buy” rating in a research note on Monday, June 1st. Wall Street Zen downgraded shares of CVS Health from a “buy” rating to a “hold” rating in a report on Monday, June 29th. Weiss Ratings restated a “hold (c)” rating on shares of CVS Health in a research report on Friday, May 8th. Bank of America boosted their price objective on shares of CVS Health from $100.00 to $110.00 and gave the stock a “buy” rating in a report on Monday, June 22nd. Finally, DA Davidson upped their price objective on shares of CVS Health from $80.00 to $100.00 and gave the company a “buy” rating in a research report on Thursday, May 7th. Twenty-one analysts have rated the stock with a Buy rating and four have given a Hold rating to the company’s stock. According to data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and an average price target of $101.28.

CVS Health Company Profile

CVS Health Corporation is a diversified healthcare company that operates a large network of retail pharmacies, pharmacy benefit management services and health care solutions. Headquartered in Woonsocket, Rhode Island, the company traces its roots to the early 1960s and has grown into an integrated provider of prescription drugs, over‑the‑counter products, clinical services and health insurance offerings. Its operating model combines retail pharmacy locations and in‑store clinics with broader pharmacy and health plan capabilities.

Key business activities include CVS Pharmacy retail operations, MinuteClinic walk‑in medical clinics and HealthHUB locations that offer expanded clinical services.